1,621 reports of this reaction
3.0% of all RITONAVIR reports
#3 most reported adverse reaction
ANXIETY is the #3 most commonly reported adverse reaction for RITONAVIR, manufactured by AbbVie Inc.. There are 1,621 FDA adverse event reports linking RITONAVIR to ANXIETY. This represents approximately 3.0% of all 53,209 adverse event reports for this drug.
RITONAVIR has an overall safety score of 85 out of 100. Patients taking RITONAVIR who experience anxiety should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANXIETY is a less commonly reported adverse event for RITONAVIR, but still significant enough to appear in the safety profile.
In addition to anxiety, the following adverse reactions have been reported for RITONAVIR:
The following drugs have also been linked to anxiety in FDA adverse event reports:
ANXIETY has been reported as an adverse event in 1,621 FDA reports for RITONAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANXIETY accounts for approximately 3.0% of all adverse event reports for RITONAVIR, making it one of the most commonly reported side effect.
If you experience anxiety while taking RITONAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.